A randomized clinical trial has been conducted to evaluate the safety and efficacy of a one-dose nocturnal treatment for self-limited epilepsy with centrotemporal spikes. The treatment being tested is levetiracetam, administered at night. The results of this trial are being reported, although the outcomes are not specified in the available information.